XML 54 R29.htm IDEA: XBRL DOCUMENT v3.20.2
SEGMENT INFORMATION (Tables)
6 Months Ended
Jun. 30, 2020
Segment Reporting [Abstract]  
Information About Reportable Segments and Reconciliation of Segment Net Sales to Consolidated Net Sales and Segment Pre-Tax Income to Consolidated Pre-Tax Income
The table below presents information about Edwards Lifesciences' reportable segments (in millions):
 
Three Months Ended   
June 30,
 
Six Months Ended   
June 30,
 
2020
 
2019
 
2020
 
2019
Segment Net Sales
 

 
 

 
 

 
 

United States
$
516.2

 
$
624.9

 
$
1,183.6

 
$
1,187.7

Europe
206.9

 
237.2

 
454.4

 
464.5

Japan
105.3

 
113.7

 
215.1

 
212.9

Rest of World
103.8

 
107.7

 
208.2

 
204.5

Total segment net sales
$
932.2

 
$
1,083.5

 
$
2,061.3

 
$
2,069.6

Segment Operating Income
 

 
 

 
 

 
 

United States
$
345.4

 
$
427.6

 
$
810.2

 
$
810.9

Europe
104.0

 
122.3

 
232.0

 
241.7

Japan
69.0

 
71.1

 
140.7

 
132.1

Rest of World
34.7

 
32.3

 
69.6

 
63.1

Total segment operating income
$
553.1

 
$
653.3

 
$
1,252.5

 
$
1,247.8


The table below presents reconciliations of segment net sales to consolidated net sales and segment operating income to consolidated pre-tax income (in millions):
 
Three Months Ended   
June 30,
 
Six Months Ended   
June 30,
 
2020
 
2019
 
2020
 
2019
Net Sales Reconciliation
 

 
 

 
 

 
 

Segment net sales
$
932.2

 
$
1,083.5

 
$
2,061.3

 
$
2,069.6

Foreign currency
(7.2
)
 
3.4

 
(7.6
)
 
10.3

Consolidated net sales
$
925.0

 
$
1,086.9

 
$
2,053.7

 
$
2,079.9

Pre-tax Income Reconciliation
 

 
 

 
 

 
 

Segment operating income
$
553.1

 
$
653.3

 
$
1,252.5

 
$
1,247.8

Unallocated amounts:
 

 
 

 
 

 
 

Corporate items
(333.0
)
 
(389.1
)
 
(673.7
)
 
(688.9
)
Special charge (Note 4)

 

 

 
(24.0
)
Intellectual property litigation expenses
(379.9
)
 
(7.0
)
 
(392.4
)
 
(11.6
)
Change in fair value of contingent consideration liabilities, net
(19.6
)
 
(8.0
)
 
(17.4
)
 
(14.7
)
Foreign currency
9.7

 
18.3

 
19.4

 
33.1

Consolidated operating (loss) income
(169.7
)
 
267.5

 
188.4

 
541.7

Non-operating income
1.5

 
3.8

 
7.9

 
7.6

Consolidated pre-tax (loss) income
$
(168.2
)
 
$
271.3

 
$
196.3

 
$
549.3


Enterprise-Wide Information nterprise-wide information is based on actual foreign exchange rates used in the Company's consolidated condensed financial statements.
 
Three Months Ended   
June 30,
 
Six Months Ended   
June 30,
 
2020
 
2019
 
2020
 
2019
 
(in millions)
Net Sales by Geographic Area
 

 
 

 
 

 
 

United States
$
516.2

 
$
624.9

 
$
1,183.6

 
$
1,187.7

Europe
204.7

 
241.7

 
454.0

 
476.4

Japan
106.8

 
113.1

 
216.8

 
211.5

Rest of World
97.3

 
107.2

 
199.3

 
204.3

 
$
925.0

 
$
1,086.9

 
$
2,053.7

 
$
2,079.9

Net Sales by Major Product and Service Area
 

 
 

 
 

 
 

Transcatheter Aortic Valve Replacement
$
594.3

 
$
677.7

 
$
1,336.5

 
$
1,275.4

Transcatheter Mitral and Tricuspid Therapies
6.1

 
7.0

 
16.6

 
11.3

Surgical Structural Heart
160.9

 
217.8

 
354.3

 
432.5

Critical Care
163.7

 
184.4

 
346.3

 
360.7

 
$
925.0

 
$
1,086.9

 
$
2,053.7

 
$
2,079.9


 
June 30, 2020
 
December 31, 2019
 
(in millions)
Long-lived Tangible Assets by Geographic Area
 

 
 

United States
$
991.1

 
$
849.1

Europe
141.9

 
101.5

Japan
20.1

 
21.7

Rest of World
280.5

 
269.4

 
$
1,433.6

 
$
1,241.7